Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nerdwallet Inc (NRDS) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Nerdwallet Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Nerdwallet Inc trades at $9.78 (market cap $625.17M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 47.3× Nerdwallet Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYNRDS
Market Cap
$29.60B$625.17M
Sector
HealthFinancials
52-Week High
$491.22$15.93
52-Week Low
$205.48$7.58
Enterprise Value
$27.56B$539.47M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.

NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS